Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?

Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?

The most effective therapeutic option for managing nonmuscle invasive bladder cancer (NMIBC), over the last 30 years, consists of intravesical instillations with the attenuated strain Bacillus Calmette-Guérin (the BCG vaccine). This has been performed as an adjuvant therapeutic to transurethral res...

Full description

Saved in:

Bibliographic Details
Main Authors:	Luís Lima, Mário Dinis-Ribeiro, Adhemar Longatto-Filho, Lúcio Santos
Format:	Article
Language:	English
Published:	Wiley 2012-01-01
Series:	Advances in Urology
Online Access:	http://dx.doi.org/10.1155/2012/232609
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Saudi urologists’ treatment pattern for high-risk Bacillus Calmette–Guérin naïve and Bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancer
by: Mohammad Alghafees, et al.
Published: (2025-01-01)

Tuberculous Spondylitis following Intravesical Bacillus Calmette-Guerin for Bladder Cancer
by: Masashi Miyazaki, et al.
Published: (2016-01-01)

Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer
by: Yi Luo, et al.
Published: (2011-01-01)

Hepatitis in Disseminated Bacillus Calmette-Guérin Infection
by: Markus U Göttke, et al.
Published: (2000-01-01)

Mycobacterium bovis Bacillus Calmette-Guérin-Induced Macrophage Cytotoxicity against Bladder Cancer Cells
by: Yi Luo, et al.
Published: (2010-01-01)

Bacillus Calmette-Guerin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol
by: Roberta Monardo, et al.
Published: (2025-01-01)

Bacille Calmette-Guérin Vaccination and Tuberculosis
by: Nick R Anthonisen
Published: (2005-01-01)

Immune responses of cattle vaccinated by various routes with Mycobacterium bovis Bacillus Calmette-Guérin (BCG)
by: Mitchell V. Palmer, et al.
Published: (2025-01-01)

Transitory Spontaneous Remission of Myelodysplasia in an Elderly Man while Receiving Intravesical Bacillus Calmette-Guérin for Bladder Cancer: A Case Report and Review of the Literature
by: Nigel P. Murray, et al.
Published: (2018-01-01)

Prosthetic Joint Infection due to Mycobacterium bovis after Intravesical Instillation of Bacillus Calmette-Guerin (BCG)
by: Eric Gomez, et al.
Published: (2009-01-01)

The Use of Bacille Calmette-Guérin vaccination in Children
by: David P Speert
Published: (1995-01-01)

Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer
by: Franklin D. Gaylis, et al.
Published: (2024-10-01)

Adverse Events of the BCG (Bacillus Calmette–Guérin) and Rotavirus Vaccines in a Young Infant with Inborn Error of Immunity
by: Suleiman Al-Hammadi, et al.
Published: (2020-01-01)

Sirtuins in kidney homeostasis and disease: where are we now?
by: Zhongyu Fan, et al.
Published: (2025-01-01)

BAFF and APRIL immunotherapy following Bacille Calmette-Guérin vaccination enhances protection against pulmonary tuberculosis in mice
by: Min Xie, et al.
Published: (2025-02-01)

Oncolytic Immunotherapy: Where Are We Clinically?
by: Akseli Hemminki
Published: (2014-01-01)

Polygenic risk scores for complex diseases: where are we now?
by: Marie Loh, et al.
Published: (2023-01-01)

Medical education and post pandemic challenges: where are we now?
by: Valeria Vásquez Estrada, et al.
Published: (2023-08-01)

Mycobacterial Brain Tuberculomas due to Bacille Calmette-Guérin Intravesical Chemotherapy for Bladder Cancer: A Case Report and Literature Review
by: Vitaly Golub, et al.
Published: (2011-01-01)

Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette–Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital Centers in Greece
by: Panagiotis Angelopoulos, et al.
Published: (2024-12-01)

Effectiveness of Steroid Pulse Therapy for Systemic Side Effects after Bacillus Calmette-Guérin Intravesical Instillation Therapy: A Series of Five Cases
by: Tatsuya Umemoto, et al.
Published: (2021-01-01)

Different Transcriptional Profiles of Human Monocyte-Derived Dendritic Cells Infected with Distinct Strains of Mycobacterium tuberculosis and Mycobacterium bovis Bacillus Calmette-Guérin
by: Nunzia Sanarico, et al.
Published: (2011-01-01)

Later-Life Mortality and Longevity in Late-18th and 19th-Century Cohorts. Where Are We Now, and Where Are We Heading?
by: Rick Mourist
Published: (2017-02-01)

Later-Life Mortality and Longevity in Late-18th and 19th-Century Cohorts. Where Are We Now, and Where Are We Heading?
by: Rich J. Mourits
Published: (2017-01-01)

Later-Life Mortality and Longevity in Late-18th and 19th-Century Cohorts. Where Are We Now, and Where Are We Heading?
by: Rick Mourits
Published: (2017-01-01)

Later-Life Mortality and Longevity in Late-18th and 19th-Century Cohorts. Where Are We Now, and Where Are We Heading?
by: Rick Mourits
Published: (2017-01-01)

Later-Life Mortality and Longevity in Late-18th and 19th-Century Cohorts. Where Are We Now, and Where Are We Heading?
by: Rick Mourits
Published: (2017-01-01)

Beyond bronchial thermoplasty – where to now?
by: Peter B. Noble, et al.
Published: (2025-01-01)

The Clusmy Child: Where Are We and Where Are We Going?
by: Mijna Hadders-Algra, et al.
Published: (2003-01-01)

Effect of Bacille Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2 and COVID‐19 vaccination
by: Nicole L Messina, et al.
Published: (2025-01-01)

Robotic Radical Cystectomy: Where are We Today, Where will We be Tomorrow?
by: Kyle A. Richards, et al.
Published: (2010-01-01)

Scoping review of brucellosis in Cameroon: Where do we stand, and where are we going?
by: Christopher G Laine, et al.
Published: (2020-01-01)

Current Status for Gastrointestinal Nematode Diagnosis in Small Ruminants: Where Are We and Where Are We Going?
by: Sarah Jane Margaret Preston, et al.
Published: (2014-01-01)

A Short History of the Genome-Wide Association Study: Where We Were and Where We Are Going
by: Shiro Ikegawa
Published: (2012-12-01)

Interferon (IFN)-gamma (γ) inducible protein 10 (IP-10) in the diagnosis of latent and active tuberculosis in Bacille Calmette Guerin (BCG)-vaccinated pediatric population.
by: Magdalena Druszczynska, et al.
Published: (2025-01-01)

Interferon (IFN)-gamma (γ) inducible protein 10 (IP-10) in the diagnosis of latent and active tuberculosis in Bacille Calmette Guerin (BCG)-vaccinated pediatric population
by: Magdalena Druszczynska, et al.
Published: (2025-01-01)

Genetics of Keratoconus: Where Do We Stand?
by: Khaled K. Abu-Amero, et al.
Published: (2014-01-01)

Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer
by: Beatriz Ramos, et al.
Published: (2025-02-01)

M. Nel, Identity-driven churches: Who are we and where are we going?
by: A. R. Tucker
Published: (2015-12-01)

Culturally programmed space of nursery – where we are going?
by: Marta Śliwa, et al.
Published: (2014-09-01)